- Home
- SNCY vs CGEM Comparison
SNCY vs CGEM Comparison
Compare SNCY & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCY
- CGEM
- Stock Information
- Founded
- SNCY 1982
- CGEM 2016
- Country
- SNCY United States
- CGEM United States
- Employees
- SNCY N/A
- CGEM N/A
- Industry
- SNCY Air Freight/Delivery Services
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- SNCY Consumer Discretionary
- CGEM Health Care
- Exchange
- SNCY Nasdaq
- CGEM Nasdaq
- Market Cap
- SNCY 805.7M
- CGEM 730.2M
- IPO Year
- SNCY 2021
- CGEM 2021
- Fundamental
- Price
- SNCY $16.18
- CGEM $10.26
- Analyst Decision
- SNCY Buy
- CGEM Strong Buy
- Analyst Count
- SNCY 6
- CGEM 7
- Target Price
- SNCY $18.67
- CGEM $31.67
- AVG Volume (30 Days)
- SNCY 737.0K
- CGEM 614.7K
- Earning Date
- SNCY 02-03-2025
- CGEM 03-13-2025
- Dividend Yield
- SNCY N/A
- CGEM N/A
- EPS Growth
- SNCY N/A
- CGEM N/A
- EPS
- SNCY 0.82
- CGEM N/A
- Revenue
- SNCY $1,060,877,000.00
- CGEM N/A
- Revenue This Year
- SNCY $4.23
- CGEM N/A
- Revenue Next Year
- SNCY $7.04
- CGEM N/A
- P/E Ratio
- SNCY $19.81
- CGEM N/A
- Revenue Growth
- SNCY 2.87
- CGEM N/A
- 52 Week Low
- SNCY $9.22
- CGEM $9.50
- 52 Week High
- SNCY $16.46
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- SNCY 62.23
- CGEM 34.25
- Support Level
- SNCY $15.40
- CGEM $9.50
- Resistance Level
- SNCY $16.46
- CGEM $11.31
- Average True Range (ATR)
- SNCY 0.63
- CGEM 0.77
- MACD
- SNCY 0.08
- CGEM -0.11
- Stochastic Oscillator
- SNCY 88.69
- CGEM 21.79
About SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.